Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33results about How to "Enhanced cellular uptake" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods of synthesis and use
InactiveUS6235886B1Increase the number ofGood curative effectSugar derivativesMicrobiological testing/measurementNucleotideOrganic chemistry
Oligonucleotide and nucleotide amine analogs and methods of preparing and using these compounds are provided by the present invention.
Owner:IONIS PHARMA INC
Antisense modulation of human mdm2 expression
InactiveUS6184212B1Easy assessment processReduce mdm protein levelPeptide/protein ingredientsGenetic material ingredientsDiseaseMdm2 Protein
Owner:IONIS PHARMA INC
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
InactiveUS6359124B1Loss of expressionEnhanced cellular uptakeOrganic active ingredientsBiocideBiological activationH-ras Genes
Compositions and methods are provided for the modulation of expression of the human ras gene in both the normal and activated forms. Oligonucleotides are provided that have methylene(methylimino) linkages alternating with phosphorothioate or phosphodiester linkages. Further oligonucleotides are provide that have a first region having a methylene(methylimino) linkage alternating with a phosphorothioate or phosphodiester linkage and a second region having phosphorothioate linkages. Such oligonucleotides can be used for diagnostics as well as for research purposes including methods for diagnosis, detection and treatment of conditions arising from the activation of the H-ras gene.
Owner:IONIS PHARMA INC
Heteroatomic oligonucleoside linkages
InactiveUS6087482AEnhanced cellular uptakeImprove propertiesGroup 4/14 element organic compoundsSugar derivativesRna expressionOligonucleotide
PCT No. PCT / US94 / 03536 Sec. 371 Date Sep. 18, 1995 Sec. 102(e) Date Sep. 18, 1995 PCT Filed Mar. 30, 1994 PCT Pub. No. WO94 / 22886 PCT Pub. Date Oct. 13, 1994Oligonucleotide-mimicking macromolecules that have improved nuclease resistance are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligonucleotides with four atom linking groups provide unique compounds that are useful in regulating RNA expression and in therapeutics. Methods of synthesis and use also are disclosed.
Owner:IONIS PHARMA INC
Polylactic acid-hydroxyacetic acid copolymer nano-drug carrier as well as preparation method and application thereof
ActiveCN104001178AImprove intake capacityEliminate side effectsNanomedicinePharmaceutical non-active ingredientsCrosslinked chitosanMicrosphere
The invention provides a PLGA (polylactic acid-hydroxyacetic acid) nano-drug carrier which is composed of PLGA nano microsphere kernel and an anillic aldehyde crosslinked chitosan housing. A preparation method of the polylactic acid-hydroxyacetic acid copolymer nano-drug carrier is as follows: dispersing a PLGA organic phase which takes dichloromethane and alcohol as a mixed solvent in a water phase to prepare PLGA microspheres by taking PVA (polyvinyl acetate) as an emulsifier by virtue of an one-off emulsion process; then, adding the PLGA microspheres into chitosan liquor, so that the chitosan is adsorbed on the surfaces of the PLGA microspheres, and then adding the chitosan on the surfaces of anillic aldehyde crosslinked PLGA microspheres. The product has a certain pH environmental responsiveness, can realize controlled release of the drug according to in-vivo pH environmental changes, is high in stability, strong in up-taking capacity for microsphere-coated medicaments by the cells, and has very good application prospect in the drug carrier for treating tumors.
Owner:SUN YAT SEN UNIV
Oligonucleotide modulation of cell adhesion
InactiveUS6015894AHigh expressionAvoid inhibitionBiocidePeptide/protein ingredientsDiseaseTranscription initiation site
Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to modulation cell adhesion molecules are disclosed.
Owner:IONIS PHARMA INC
Oligonucleoside linkages containing adjacent nitrogen atoms
InactiveUS6214551B1Sequencing is facilitatedConfer nuclease resistanceGroup 4/14 element organic compoundsSugar derivativesNitrogenOligonucleotide
Novel compounds that mimic and / or modulate the activity of wild-type nucleic acids. In general, the compounds contain a selected nucleoside sequence wherein the nucleosides are covalently bound through linking groups that contain adjacent nitrogen atoms.
Owner:IONIS PHARMA INC
Detection and modulation of IAPs and NAIP for the diagnosis and treatment of proliferative disease
InactiveUS7087584B2Enhanced cellular uptakeImprove stabilityVirusesSugar derivativesCancer therapyOvarian cancer
Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.
Owner:PHARMASCIENCE INC
Method of reducing angiogenesis
InactiveUS20050158280A1Easy adhesionEasy to migrateCompound screeningBiocideAngiogenesis growth factorBlood vessel
The invention features methods of identifying a compound capable of modulating angiogenesis. Further features of the invention are methods of promoting or inhibiting angiogenesis. Methods for the diagnosis of a CD39-associated condition and for determining the prognosis of a patient diagnosed with a CD39-associated condition are also disclosed.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
InactiveUS6495671B1Good curative effectEnhanced cellular uptakeSugar derivativesMicrobiological testing/measurementNucleotideOrganic chemistry
Owner:IONIS PHARMA INC
Antisense IAP oligonucleotides and uses thereof
InactiveUS7294713B2Enhanced cellular uptakeImprove stabilitySugar derivativesPeptide/protein ingredientsNegative regulatorApoptosis pathway
Owner:OTTAWA UNIV OF +1
Methods and compositions for use in spliceosome mediated RNA trans-splicing
InactiveUS20020193580A1Improve abilitiesEfficient processVectorsSugar derivativesTrans-splicingSpliceosome complex
The present invention provides methods and compositions for delivery of synthetic pre-trans-splicing molecules (synthetic PTMs) into a target cell. The compositions of the invention include synthetic pre-trans-splicing molecules (PTMs) with enhanced stability against chemical and enzymatic degradation. The synthetic PTMs are designed to interact with a natural target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA).
Owner:VIRXSYS
Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
InactiveUS20030153737A1Good curative effectEnhanced cellular uptakeSugar derivativesGenetic material ingredientsNucleotideOrganic chemistry
Owner:IONIS PHARMA INC
Template directed split and mix systhesis of small molecule libraries
ActiveUS8168381B2Increase generationEnhanced cellular uptakeSequential/parallel process reactionsSugar derivativesCombinatorial chemistryBiochemistry
Owner:NUEVOLUTION AS
Modulating Retinal Pigmented Epithelium Permeaion By Inhibiting Or Activating VEGFR-1
InactiveUS20090087424A1Enhanced cellular uptakeHigh affinityOrganic active ingredientsSenses disorderOphthalmologyDisease
Described is a method for use of an agonist or an antagonist of VEGFR-1 in the treatment or prevention of diseases wherein disorders of the retinal pigment epithelium permeation are involved.
Owner:NOVAGALI PHARMA
Methods for Diagnosing and Treating Cancer
InactiveUS20120252737A1Increasing disease-free survival timeInhibiting and slowing and stabilizing progressionOrganic active ingredientsPeptide librariesOncologyChemotherapy resistance
The invention provides methods for decreasing one or more symptoms of cancer in a patient requiring the steps of determining the activation or inactivation of the MK2 signaling pathway and, based on these determinations, administering either a MK2 inhibitor or a combination of a MK2 inhibitor and a chemotherapeutic agent, or a chemotherapeutic agent to the patient. The invention further provides methods for identifying a cancer patient that may selectively benefit from the administration of a chemotherapeutic agent, or the administration of a MK2 inhibitor or the combination of a MK2 inhibitor and a chemotherapeutic agent, requiring the steps of determining the activation or inactivation of the MK2 signaling pathway. The invention additionally provides methods and kits for diagnosing a chemotherapy-sensitive or chemotherapy-resistant cancer in a subject that require the step of (or reagents for) determining the activation or inactivation of the MK2 signaling pathway. The invention also provides methods of treating a cancer patient diagnosed as having a chemotherapy-sensitive or a chemotherapy-resistant cancer.
Owner:MASSACHUSETTS INST OF TECH
Treatment and prevention of gardnerella vaginalis infections
The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from Gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-VLY antibodies and to their use therapeutically and in a new ELISA assay of VLY toxin. Other embodiments of the invention are directed to VLY toxoids and to vaccines that use the new VLY toxoids as immunogens.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Antisense modulation of inhibitor-kappa B kinase-gamma expression
InactiveUS20030105037A1Increase viscosityEnhanced cellular uptakeSugar derivativesPeptide/protein ingredientsDiseaseAntisense oligonucleotides
Antisense compounds, compositions and methods are provided for modulating the expression of inhibitor-kappa B kinase-gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding inhibitor-kappa B kinase-gamma. Methods of using these compounds for modulation of inhibitor-kappa B kinase-gamma expression and for treatment of diseases associated with expression of inhibitor-kappa B kinase-gamma are provided.
Owner:IONIS PHARMA INC
Tumour-targeting peptide variants
PendingUS20200283532A1High binding activityEnhanced bio-distributionSsRNA viruses positive-senseIntegrin superfamilyTumour targetingΑvβ6 integrin
The present invention provides a peptide that selectively binds αvβ6 integrin, the peptide having an amino acid sequence comprising the motif X1BnRGDLX2X3X4ZmX5, wherein X1 is any D-amino acid, Bn is a sequence of any n amino acids, which may be natural or unnatural, D- or L-, and may be the same or different, wherein n is a number between 1 and 10, X2 and X3 are independently selected from any amino acid, X4 is Leu or Ile, Zm is a sequence of any m amino acids, which may be natural or unnatural, D- or L-, and may be the same or different, wherein m is a number between 1 and 10, X5 is any L- or D-amino acid. Also provided are conjugates comprising said peptide, pharmaceutical compositions comprising said peptide or said conjugates, and uses of said peptide, conjugate or composition, for example, in the treatment, imaging and / or diagnosis of an αvβ6-expressing tumour in a mammalian subject.
Owner:CANCER RES TECH LTD
Antisense IAP oligonucleotides and uses thereof
InactiveUS20070142316A1Enhanced cellular uptakeImprove stabilitySugar derivativesPeptide/protein ingredientsNegative regulatorAntisense oligonucleotides
The present invention features antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
Owner:AEGERA THERAPEUTICS INC +1
A polylactic acid-glycolic acid copolymer nano drug carrier and its preparation method and application
ActiveCN104001178BImprove adhesionEnhanced cellular uptakeNanomedicinePharmaceutical non-active ingredientsCrosslinked chitosanMicrosphere
The invention provides a PLGA (polylactic acid-hydroxyacetic acid) nano-drug carrier which is composed of PLGA nano microsphere kernel and an anillic aldehyde crosslinked chitosan housing. A preparation method of the polylactic acid-hydroxyacetic acid copolymer nano-drug carrier is as follows: dispersing a PLGA organic phase which takes dichloromethane and alcohol as a mixed solvent in a water phase to prepare PLGA microspheres by taking PVA (polyvinyl acetate) as an emulsifier by virtue of an one-off emulsion process; then, adding the PLGA microspheres into chitosan liquor, so that the chitosan is adsorbed on the surfaces of the PLGA microspheres, and then adding the chitosan on the surfaces of anillic aldehyde crosslinked PLGA microspheres. The product has a certain pH environmental responsiveness, can realize controlled release of the drug according to in-vivo pH environmental changes, is high in stability, strong in up-taking capacity for microsphere-coated medicaments by the cells, and has very good application prospect in the drug carrier for treating tumors.
Owner:SUN YAT SEN UNIV
Treatment and prevention of Gardnerella vaginalis infections
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Detection and modulation of IAPS and NAIP for the diagnosis and treatment of proliferative disease
InactiveUS20060189563A1Enhanced cellular uptakeImprove stabilityVirusesPeptide/protein ingredientsCancer therapyOvarian cancer
Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.
Owner:AEGERA THERAPEUTICS INC
Oligo-guanidines based cellular transporter comprising heterocyclic rings with hydrophobic and/or lipophilic groups at n-terminal for effective delivery of nonpenetrable cargos in-vitro and in-vivo
ActiveUS20190002408A1Improve permeabilityEnhanced cellular uptakeOrganic active ingredientsOrganic chemistryMorpholineHeteroatom
An oligo-guanidine as cell penetrating agents / carriers includes a heterocyclic ring including 4-aminopiperidine, piperazine, morpholine having at least one N-terminal based heterocyclic ring or at least one O-heteroatom based heterocyclic ring tailored with hydrophobic and / or lipophilic group. The oligo-guanidine is adapted as an effective molecular transporter to transport and / or delivery therapeutics, therapeutic candidates, probes, or other molecules of interest across biological barriers including oligonucleotides. Advantageously, the oligo-guanidine is capable of being internalized into cells (in-vitro and in-vivo) with enhanced cellular uptake in nanomolar concentration.
Owner:INDIAN ASSOC FOR THE CULTIVATION OF SCI
Oligo-guanidines based cellular transporter comprising heterocyclic rings with hydrophobic and/or lipophilic groups at N-terminal for effective delivery of nonpenetrable cargos in-vitro and in-vivo
ActiveUS10919857B2Improve permeabilityEnhanced cellular uptakeOrganic active ingredientsOrganic chemistryMorpholineHeteroatom
An oligo-guanidine as cell penetrating agents / carriers includes a heterocyclic ring including 4-aminopiperidine, piperazine, morpholine having at least one N-terminal based heterocyclic ring or at least one O-heteroatom based heterocyclic ring tailored with hydrophobic and / or lipophilic group. The oligo-guanidine is adapted as an effective molecular transporter to transport and / or delivery therapeutics, therapeutic candidates, probes, or other molecules of interest across biological barriers including oligonucleotides. Advantageously, the oligo-guanidine is capable of being internalized into cells (in-vitro and in-vivo) with enhanced cellular uptake in nanomolar concentration.
Owner:INDIAN ASSOC FOR THE CULTIVATION OF SCI
Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
ActiveUS10260089B2Efficient solutionEffective absorptionMicrobiological testing/measurementPeptidesNucleobaseAvidity
Peptide nucleic acids containing thymidine and 2-aminopyridine (M) nucleobases formed stable and sequence selective triple helices with double stranded RNA at physiologically relevant conditions. The M-modified PNA displayed unique RNA selectivity by having two orders of magnitude higher affinity for the double stranded RNAs than for the same DNA sequences. Preliminary results suggested that nucleobase-modified PNA could bind and recognize double helical precursors of microRNAs.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Antisense IAP oligonucleotides and uses thereof
InactiveUS20070123481A1Enhanced cellular uptakeImprove stabilitySugar derivativesPeptide/protein ingredientsApoptosisNegative regulator
The present invention features antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.
Owner:AEGERA THERAPEUTICS INC +1
Treatment and Prevention of Gardnerella Vaginalis Infections
InactiveUS20150010579A1Good curative effectReduce riskAntibacterial agentsBacterial antigen ingredientsToxoidToxin
The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from Gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-VLY antibodies and to their use therapeutically and in a new ELISA assay of VLY toxin. Other embodiments of the invention are directed to VLY toxoids and to vaccines that use the new VLY toxoids as immunogens.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Mitotic Progression Genes and Methods of Modulating Mitosis
InactiveUS20090215876A1Enhanced cellular uptakeImprove stabilityOrganic active ingredientsHydrolasesDiseaseMitotic progression
Owner:SANOFI AVENTIS SA +1
Inhibition of polyomavirus replication
PendingUS20210010004A1Enhanced cellular uptakeImprove stabilityOrganic active ingredientsSplicing alterationMolecular biologyViral replication
The invention relates to antisense molecules and methods for modulating splicing of polyomavirus T antigen pre-mRNA. In one aspect the invention relates to an antisense oligonucleotide 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length which comprises a sequence that is the reverse complement of a contiguous stretch of at least 12 nucleobases of a polyomavirus T-antigen pre-mRNA and which antisense oligonucleotide can modulate splicing of said T-antigen pre-mRNA in a cell.
Owner:ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com